Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067233 | 1.00 | MMP13 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460133 | 1.00 | MMP13 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL2239710 | 0.91 | GSTP1 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL2239712 | 0.91 | GSTP1 (0.48) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL5147914 | 0.90 | ALDH1A1 (0.55) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460172 | 0.90 | MMP13 (0.46) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL18811796 | 0.90 | THRB (0.46) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460171 | 0.89 | CA1 (0.45) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL1460170 | 0.89 | CA1 (0.45) | MMP13CA1CA2MMP1MMP2 | |
| SCHEMBL28085110 | 0.85 | MMP13 (0.52) | MMP13CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | AFFYMAX, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002011732-A1 | NOVEL BICYCLIC AND TRICYCLIC PYRROLIDINE DERIVATIVES AS GNRH ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | GNRHR, FSHR, LHCGR | MMP13 4046/4885CA1 3142/4885CA2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.